Leadership
Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.
CEO Albert Bourla said Starboard Value’s push for change at Pfizer is coming 15 months late as the company is already executing a five-point plan to cut costs and pivot on strategy.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting
Recent moves in the industry include changes at the top at enGene Holdings, which also acquires chief technology officer from Albireo Pharma.
Positive data on its anti-TIGIT antibody belrestotug meant ITeos provided one of the biggest stories at ESMO this year. CEO Michel Detheux told Scrip there was much more to come from the US-headquartered biotech founded in Belgium.
CEO of Sumitomo Pharma America unit, Adele M. Gulfo, draws from experiences working across companies including Pfizer, to advise on go-to-market strategies for a portfolio across primary care to rare disease.
Sanofi’s EVP (general medicines), Olivier Charmeil, talks about pharma’s evolving go-to-market strategies that enmesh a more personalized, data-driven approach, why the medical, legal, and regulatory (MLR) review process needs to be faster and also impressive learnings from Amazon, Netflix and Ikea around building customer experience.
In a video interview, Nandini Piramal, chairperson of Piramal Pharma, speaks with Scrip about a focus on on-patent products, an integrated ADC offering, a measured approach to the proposed BIOSECURE Act and the company’s strategy to double revenue to about $2bn
The latest reorganization comes after a mid-stage pipeline asset failed in Alzheimer’s disease and Parkinson’s disease.
Recent moves in the industry include changes at the top at Defence Therapeutics, Trevena and Neurocrine Biosciences, plus Alpha Cognition gets a new chief Financial officer.
CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.
Axcynsis is developing a derivative of the chemotherapy agent Yondelis as a new payload, which the Singapore venture will first apply to a Claudin 6-targeting ADC it plans to take into a Phase I trial in the US, its chairman, CEO and founder tells Scrip in an interview.
Recent moves in the industry include C-suite changes at Cybin, Biomarin and Nuvation Bio, plus Novita Pharmaceuticals gets a new chief executive officer.
Syngene’s CEO talks to Scrip about how the firm is deepening capabilities in areas like ADCs, PROTACs and why the US Inflation Reduction Act may not necessarily shrink outsourced small molecule work. The executive also shares his view on the China ‘rebalancing’ trend amid geopolitical tensions and the US BIOSECURE Act.
Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.
Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.
CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.
The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.
Recent changes in the industry include changes at the top at Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.
The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.